Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
•
Stereotactic Body Radiotherapy
•
Prostate Cancer
What fractionation and dose constraints do you use for prostate SBRT?
Answer from: Radiation Oncologist at Community Practice
UCLA King Protocol8 Gy x5PTV 95% of PTV volume to get 95-110% rx doseRectum V50 (20 Gy) < 50%V80 (32 Gy) < 20%V90 (36 Gy) < 10 %V100 (40Gy) < 5%BladderV50 (20 Gy) < 40%V100 (40 Gy) < 1.1%Femurs V40 (16 Gy) < 5%Small Bowel V50 (20Gy) < 1%
Sign in or Register to read more
380
Related Questions
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
Would you ever omit or reduce prostate bed radiation in a post-prostatectomy patient who develops recurrence in pelvic LNs?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
How would you plan sequencing of an MRI-directed prostate nodule micro-boost when doing a sequential plan?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?